HYTN Innovations Inc. is pleased to announce that it has received a new set of import permits from the United Kingdom’s Home Office and corresponding export permits from Health Canada.

HYTN Innovations Inc. is pleased to announce the receipt of an initial purchase order under manufacturing and pricing agreements (the Agreements) with SNDL Inc. (NASDAQ: SNDL) ("SNDL"), one of the world’s largest vertically integrated cannabis companies.

HYTN is pleased to announce its successful export of cannabis to the United Kingdom’s 4C LABS. This announcement follows the news from November 28, 2024, that the Company received its first international order for products manufactured under its recently awarded Good Manufacturing Practices (GMP) designation.

HYTN is pleased to announce the receipt of initial orders and import permits from the UK's 4C Labs, marking a significant milestone in their partnership. This achievement allows HYTN to begin exporting premium cannabis-based pharmaceuticals to the UK under the company's recently established agreements.

HYTN is pleased to announce that it has engaged bullVestor Medien GmbH (“bullVestor”) to provide marketing services for an anticipated period of 6 months, or until budget exhaustion, commencing on November 15th, 2024, and provided that the term of the marketing services may be extended or shortened at the discretion of management.

HYTN proudly announces that it has received an additional Good Manufacturing Practices (GMP) certification for its Kelowna manufacturing facility. This certification now includes distribution as a licenced activity under HYTN's Drug Establishment Licence (DEL) issued by Health Canada.

HYTN is pleased to announce, further to its news release dated July 19, 2024, that it has filed a Business Acquisition Report (BAR) in respect of its acquisition of Prism Scientific Labs Inc. The BAR may be found under the Company’s profile on SEDAR+ (www.sedarplus.ca).

HYTN is proud to announce the establishment of international manufacturing and pricing agreements (the Agreements) with 4C LABS, a leading importer and distributor of cannabis-based pharmaceuticals in the United Kingdom.

“HYTN”, a pharmaceutical company specializing in the development, formulation, and manufacturing of products containing psychoactive and psychotropic compounds, including cannabis and psilocybin, is pleased to announce its approval for trading on the OTC PINK Market ("OTC PINK") effective July 29th, 2024, under the trading symbol “HYTNF”.

"HYTN", a leader in the development, formulation, and manufacturing of psychoactive and psychotropic compounds, including cannabis and psilocybin, is pleased to announce, further to its news release dated June 13, 2024, the completion of its acquisition (“Acquisition”) of all of the issued and outstanding share capital of Prism Scientific Labs Inc. (Prism), a company focussed on the research and development of psychedelic and psychoactive compounds, with a particular emphasis on enhancing tryptamine yields in psychedelic mushrooms.

“HYTN”, a leader in the development, formulation, and manufacturing of products containing psychoactive and psychotropic compounds, including cannabis and psilocybin, is pleased to announce that it has been granted a Drug Establishment License (DEL) by Health Canada.

HYTN is pleased to announce that that it has entered into an agreement (the “Purchase Agreement”) to acquire (the “Transaction”) 100% of the issued and outstanding share capital of Prism Scientific Labs Inc.

HYTN is pleased to announce that it has engaged the services of Independent Trading Group (”ITG”) as a market maker for its shares traded on the Canadian Securities Exchange (“CSE”).

HYTN is pleased to announce the results of its annual general and special meeting of shareholders held on May 23, 2024 (the “AGSM”).

is pleased to announce that it has closed its previously announced nonbrokered private placement of units of the Company (“Units”) by issuing a total of 9,980,670 Units at a price of $0.075 per Unit (the “Offering”) for aggregate gross proceeds of $748,550.25.